You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

Investigational Drug Information for GLPG1690


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for GLPG1690?

GLPG1690 is an investigational drug.

There have been 9 clinical trials for GLPG1690. The most recent clinical trial was a Phase 2 trial, which was initiated on November 5th 2018.

The most common disease conditions in clinical trials are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Idiopathic Interstitial Pneumonias. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].

There are six US patents protecting this investigational drug and two hundred and four international patents.

Recent Clinical Trials for GLPG1690
TitleSponsorPhase
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisGalapagos NVPhase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisGalapagos NVPhase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareGalapagos NVPhase 3

See all GLPG1690 clinical trials

Clinical Trial Summary for GLPG1690

Top disease conditions for GLPG1690
Top clinical trial sponsors for GLPG1690

See all GLPG1690 clinical trials

US Patents for GLPG1690

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GLPG1690 ⤷  Try for Free Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) ⤷  Try for Free
GLPG1690 ⤷  Try for Free Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) ⤷  Try for Free
GLPG1690 ⤷  Try for Free Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Galapagos NV (Mechelen, BE) ⤷  Try for Free
GLPG1690 ⤷  Try for Free Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) ⤷  Try for Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GLPG1690

Drugname Country Document Number Estimated Expiration Related US Patent
GLPG1690 Argentina AR095280 2033-03-14 ⤷  Try for Free
GLPG1690 Australia AU2014231009 2033-03-14 ⤷  Try for Free
GLPG1690 Australia AU2017286828 2033-03-14 ⤷  Try for Free
GLPG1690 Australia AU2019204539 2033-03-14 ⤷  Try for Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Development Update and Market Projection for GLPG1690: A Comprehensive Overview

Last updated: January 3, 2025

Introduction to GLPG1690

GLPG1690 is a small molecule, selective autotaxin inhibitor developed by Galapagos, a biotechnology company known for its innovative approaches to drug discovery. This drug candidate was specifically designed to target idiopathic pulmonary fibrosis (IPF), a debilitating and progressive lung disease with limited treatment options.

Mechanism of Action and Target Identification

GLPG1690 works by inhibiting autotaxin, an enzyme implicated in the pathogenesis of IPF. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed GLPG1690 to selectively inhibit this enzyme. The mechanism of action involves reducing the levels of lysophosphatidic acid (LPA), a bioactive lipid produced by autotaxin, which is associated with fibrosis and disease progression in IPF[1][4].

Pre-Clinical and Early Clinical Trials

In pre-clinical models, GLPG1690 showed promising results in halting disease progression relevant to IPF. The drug successfully completed a Phase 1 trial in 2015, demonstrating favorable safety and tolerability profiles, as well as high target engagement in healthy volunteers[4].

The FLORA Phase 2a trial, conducted in 2017, was a significant milestone. This 12-week, multicenter, randomized, double-blind, placebo-controlled trial showed that GLPG1690 stabilized forced vital capacity (FVC) in IPF patients, while the placebo arm exhibited the expected decline. The treatment group also showed a clear reduction in serum LPA18:2, a biomarker for autotaxin inhibition. GLPG1690 was generally well-tolerated, with adverse event rates similar to those in the placebo group[4].

Phase 3 Trials and Regulatory Feedback

Following the positive results from the FLORA trial, Galapagos designed a worldwide Phase 3 program, known as the ISABELA trials, to further evaluate GLPG1690 in IPF patients. This program was intended to support New Drug Application (NDA) and Market Authorization Application (MAA) submissions in the United States and European Union, respectively. However, the development of GLPG1690 was subsequently discontinued due to an unfavorable risk/benefit profile observed by an Independent Data Monitoring Committee (IDMC) during the Phase 3 trials[2].

Discontinuation and Impact

The discontinuation of GLPG1690's development was a significant setback for both Galapagos and patients suffering from IPF. Despite the promising early results, the Phase 3 trials revealed a risk profile that did not justify continued development. This decision highlights the challenges and uncertainties inherent in drug development, particularly for complex and debilitating diseases like IPF[2].

Market Projection and Context

The global idiopathic pulmonary fibrosis treatment market is projected to grow, driven by the increasing prevalence of the disease and the need for effective treatments. While GLPG1690 is no longer in development, other drugs and therapies are being explored to fill this gap.

Current Market Landscape

The market for IPF treatments is characterized by a limited number of approved therapies, primarily pirfenidone and nintedanib, which have shown some efficacy in slowing disease progression but do not halt it entirely. New candidates, such as BI 1015550, a PDE type 4B compound, are in various stages of clinical trials and may offer alternative treatment options in the future[3].

Future Growth and Trends

The idiopathic pulmonary fibrosis treatment market is expected to grow from 2024 to 2031, driven by increasing patient numbers, advancements in pharmacotherapy, and a growing awareness of the disease. The market will likely see the introduction of new therapies, including small molecules and biologics targeting various pathways involved in fibrosis[5].

Key Takeaways

  • Mechanism and Target: GLPG1690 is a selective autotaxin inhibitor targeting IPF.
  • Clinical Trials: Positive Phase 2 results were followed by discontinuation in Phase 3 due to an unfavorable risk/benefit profile.
  • Market Impact: The discontinuation of GLPG1690 highlights the challenges in drug development for IPF.
  • Market Growth: The IPF treatment market is expected to grow with new therapies and increasing patient numbers.

FAQs

What is GLPG1690 and how does it work?

GLPG1690 is a small molecule that inhibits autotaxin, an enzyme involved in the progression of idiopathic pulmonary fibrosis (IPF). It reduces the levels of lysophosphatidic acid (LPA), a bioactive lipid associated with fibrosis.

What were the results of the FLORA Phase 2a trial for GLPG1690?

The FLORA trial showed that GLPG1690 stabilized forced vital capacity (FVC) in IPF patients over a 12-week period and was generally well-tolerated.

Why was the development of GLPG1690 discontinued?

The development of GLPG1690 was discontinued due to an unfavorable risk/benefit profile observed during the Phase 3 trials by an Independent Data Monitoring Committee (IDMC).

What is the current state of the IPF treatment market?

The IPF treatment market is characterized by a limited number of approved therapies and is expected to grow with the introduction of new treatments targeting various pathways involved in fibrosis.

Are there other promising drug candidates for IPF in development?

Yes, other drug candidates like BI 1015550, a PDE type 4B compound, are in various stages of clinical trials and may offer alternative treatment options for IPF patients.

Sources

  1. Galapagos Press Release: "GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS" - May 20, 2018.
  2. Galapagos Press Release: "Galapagos 2021 results set stage for future growth" - February 24, 2022.
  3. MDPI Article: "An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis" - 2023.
  4. Galapagos Press Release: "GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial" - August 9, 2017.
  5. iHealthcareAnalyst Report: "Idiopathic Pulmonary Fibrosis Treatment Market and Forecast 2024-2031" - 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.